Skip to main content
Full access
Communications and Updates
Published Online: 1 May 2012

A Fatal Case of Adynamic Ileus Following Initiation of Clozapine

To the Editor: In patients with treatment-refractory schizophrenia, clozapine is considered the most effective anti-psychotic medication (1). However, it has side effects that can limit its usage (2). A seldom-encountered but significant side effect is adynamic ileus. We present here the case of a patient with schizophrenia who developed adynamic ileus within 9 days of initiation of clozapine.

Case Report

“Mr. B.,” a 65-year-old man with schizophrenia, was involuntarily admitted for psychotic exacerbation. On admission, he was taking 30 mg/day of olanzapine to abate symptoms of psychosis, aggression, and dangerous wandering. Despite intensive case management and adequate trials with haloperidol, risperidone, and olanzapine, he was refractory to treatment and required annual hospitalizations. Mr. B had not had a previous trial of clozapine. After obtaining informed consent, we initiated treatment with clozapine and increased the dosage by 12.5 mg/day, while olanzapine was gradually reduced with plans to discontinue. Docusate sodium, 100 mg b.i.d., was initiated prophylactically. He was not taking additional anticholinergic medications.
Shortly after the initiation of clozapine, Mr. B complained of malaise and anorexia followed by nausea, vomiting, and diarrhea. Nine days after initiation of clozapine, which was now at a dosage of 100 mg/day and the olanzapine dosage at 10 mg/day, he became tachypneic and hypotensive. He was transferred to the intensive care unit, treated with pressors, and intubated.
Mr. B's medical history included gastroesophageal reflux disease, a prostatetectomy for benign prostatic hyperplasia, and a remote history of small bowel obstruction that was managed conservatively, while olanzapine was continued for treatment of psychosis.
While in the intensive care unit, a CT scan of the abdomen led to the diagnosis of adynamic ileus. A chest X-ray revealed an infiltrate suggestive of aspiration, and colonoscopy demonstrated diverticulosis without evidence of malignancy. Clozapine was discontinued, and olanzapine, which had been discontinued during evaluation in the intensive care unit, was restarted. The patient stabilized after 3 weeks and was returned to the psychiatric unit.
Within 10 days, the patient again developed diarrhea, tachypnea, and tachycardia requiring medical stabilization. He died 3 days later. Although an autopsy was not performed, it was suspected that he died from complications of ileus.

Discussion

Adynamic ileus is an infrequently encountered but serious complication of clozapine with a mortality rate approaching 28% (3). Anticholinergic effects are thought to be the cause (4). One study found that the median time from the first dose of clozapine to onset of ileus was greater than 1,500 days (4). In this case, the patient developed ileus within 9 days of initiation of clozapine and died 5 weeks later. He had no known risk factors for ileus such as malignancy or recent surgery; however, he was taking olanzapine, another highly anticholinergic medication, at the time of decompensation. It is possible that the combination of these two drugs, even for a brief duration for cross-tapering, contributed to this patient's rapid development of ileus and subsequent death. This case highlights the importance of carefully monitoring patients taking clozapine for potentially fatal gastrointestinal side effects, especially when treatment includes other anticholinergics, as this may result in serious consequences in a much shorter time frame than the literature has suggested (4).

Footnote

Accepted for publication in February 2012.

References

1.
McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, Keefe RSE, Davis CE, Severe J, Hsiao JK: Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006; 163:600–610
2.
Asenjo Lobos C, Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Leucht S: Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2010; 11:CD006633
3.
Palmer SE, McLean RM, Ellis PM, Harrison-Woolrych M: Life-threatening clozapine-induced gastrointestinal hypomotility: an analysis of 102 cases. J Clin Psychiatry 2008; 69:759–768
4.
Nielsen J, Meyer JM: Risk factors for ileus in patients with schizophrenia. Schizophr Bull (Epub ahead of print, Nov 26, 2010)

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 538
PubMed: 22549212

History

Accepted: February 2012
Published online: 1 May 2012
Published in print: May 2012

Authors

Details

Sarah M. Fayad, M.D.
Dawn M. Bruijnzeel, M.D.

Funding Information

The authors report no financial relationships with commercial interests.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share